<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00649844</url>
  </required_header>
  <id_info>
    <org_study_id>A1281039</org_study_id>
    <nct_id>NCT00649844</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs</brief_title>
  <acronym>MOZART</acronym>
  <official_title>Double Blind, Double-Dummy Multicenter, Parallel Group Comparison Of The Efficacy And The Tolerability Of Ziprasidone Vs. Clozapine In Schizophrenic Patients Who Are Refractory And/Or Intolerant To Antipsychotic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of ziprasidone and clozapine
      in schizophrenic patients who are resistant and/or intolerant to antipsychotic treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to endpoint in Positive and Negative Syndrome Scale (PANSS) total scores</measure>
    <time_frame>Until Final Visit (within 18 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders, based on change from baseline to endpoint in PANSS total score</measure>
    <time_frame>Until Final Visit (within 18 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in Clinical Global Impressions-Severity (CGI-S) scores</measure>
    <time_frame>Baseline and weekly from Weeks 1-18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discontinuation</measure>
    <time_frame>Up to 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in cognitive function assessments, including Rey serial verbal learning test, Stroop Color Word test, and Trail Making Test</measure>
    <time_frame>Baseline and Weeks 12 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in Global Assessment of Functioning (GAF) scores</measure>
    <time_frame>Baseline and Week 8, 12, and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Modified Resource Utilization Questionnaire (RUQ) scores</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in Drug Attitude Inventory (DAI) scores</measure>
    <time_frame>Screening and Weeks 1, 8, 12, and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in PANSS subscale scores</measure>
    <time_frame>Baseline and weekly from Weeks 1-18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Weekly from Weeks 1-18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in Calgary Depression Scale (CDSS) scores</measure>
    <time_frame>Baseline and Weeks 8, 12, and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Caregiver Activity Survey (CAS)</measure>
    <time_frame>Screening and Weeks 1, 8, 12, and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory tests</measure>
    <time_frame>Screening and weekly from Weeks 1-18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in electrocardiogram</measure>
    <time_frame>Screening and Weeks 1, 8, 12, and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in movement disorder rating scales, including Barnes Akathisia Rating Scale, Abnormal Involuntary Movement Scale, and Simpson-Angus Scale</measure>
    <time_frame>Baseline and Weeks 1, 8, 12, and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in Clinical Global Impressions-Improvement (CGI-I) scores</measure>
    <time_frame>Baseline and weekly from Weeks 1-18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in Patient Preference Scale (PPS) scores</measure>
    <time_frame>Screening and Weeks 1, 8, 12, and 18</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozapine</intervention_name>
    <description>Clozapine 25 or 100 mg tablets. Patients were initially titrated over the first 10 days to 300 mg/day and remained at this dose for 1 week. Thereafter, the dose could be varied between 250 and 600 mg/day based on response and tolerability for a total treatment duration of 18 weeks</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>Ziprasidone 40, 60, or 80 mg capsules. Patients were initially titrated over the first 3 days to 80 mg/day, which could subsequently be increased to between 80 and 160 mg/day based on response and tolerability for a total treatment duration of 18 weeks</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Geodon, Zeldox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CGI - S ≥4

          -  PANSS ≥ 80

          -  Inpatients or outpatients

        Exclusion Criteria:

          -  Patients with a history of myeloproliferative diseases, history of granulocytopenia,
             agranulocytosis due to a drug

          -  Diagnosis of substance dependence within previous 3 months using DSM-IV criteria

          -  History of seizure

          -  Organic mental disease, including mental retardation or epilepsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Citta' Di Castello</city>
        <state>Perugia</state>
        <zip>06012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bassano Del Grappa</city>
        <state>Vicenza</state>
        <zip>36061</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brescia</city>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cagliari</city>
        <zip>09045</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cagliari</city>
        <zip>09124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Guardiagrele (ch)</city>
        <zip>66016</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Messina</city>
        <zip>98100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montichiari (brescia)</city>
        <zip>25018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00137</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trieste</city>
        <zip>34126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281039&amp;StudyName=A%20study%20comparing%20the%20efficacy%20and%20tolerability%20of%20ziprasidone%20vs.%20clozapine%20for%20the%20treatment%20of%20schizophrenia%20in%20patients%20who%20continue</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>September 24, 2009</last_update_submitted>
  <last_update_submitted_qc>September 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

